Does Aetna Cover Wegovy? Insurance Guide 2026

Weight loss and diabetes management have entered a new era with the introduction of Wegovy, a once-weekly injectable medication that has shown remarkable efficacy in clinical trials. As more patients seek access to this groundbreaking treatment, one of the most pressing questions is whether insurance providers like Aetna cover Wegovy. This comprehensive guide explores Aetna’s coverage policies for Wegovy in 2026, offering evidence-based insights into eligibility, costs, and steps to secure approval. Whether you’re managing obesity or type 2 diabetes, understanding how to navigate Aetna’s system can make all the difference in accessing Wegovy.

---

Does Aetna Cover Wegovy for Diabetes?

Aetna’s coverage of Wegovy for diabetes management is contingent on specific clinical criteria and the medication’s FDA-approved indications. Wegovy, which contains the active ingredient semaglutide, was initially approved by the FDA in 2021 for chronic weight management. However, its sister drug, Ozempic (also semaglutide), has been approved for type 2 diabetes since 2017. While Wegovy is not FDA-approved for diabetes, Aetna may cover it for diabetic patients under certain circumstances, particularly if the patient meets weight-related comorbidities or has failed other diabetes treatments.

Aetna’s policy often aligns with the American Diabetes Association (ADA) guidelines, which recognize the role of GLP-1 receptor agonists like semaglutide in improving glycemic control and promoting weight loss in diabetic patients. In 2026, Aetna’s coverage for Wegovy in diabetes typically requires documentation of a body mass index (BMI) of 27 or higher with at least one weight-related condition, such as hypertension or dyslipidemia. Additionally, patients must demonstrate inadequate glycemic control with metformin or other first-line diabetes medications.

Clinical trials, such as the SUSTAIN program, have shown that semaglutide significantly reduces HbA1c levels and promotes weight loss in diabetic patients. These findings support Aetna’s potential approval of Wegovy for diabetes when prescribed off-label. However, patients should be prepared to provide detailed medical records, including prior treatment failures, to justify the need for Wegovy over other diabetes medications.

---

Does Aetna Cover Wegovy for Weight Loss?

Aetna’s coverage of Wegovy for weight loss is more straightforward, as the medication is FDA-approved for chronic weight management in adults with obesity or overweight individuals with weight-related conditions. In 2026, Aetna’s policy for Wegovy coverage typically requires patients to meet one of the following criteria: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or obstructive sleep apnea.

The STEP clinical trial program, which evaluated Wegovy for weight loss, demonstrated an average weight reduction of 15-20% over 68 weeks, far surpassing the results of lifestyle interventions alone. These findings have influenced Aetna’s coverage policies, as Wegovy is recognized as a medically necessary treatment for obesity, a chronic disease recognized by the American Medical Association (AMA) and the World Health Organization (WHO).

However, Aetna often requires patients to participate in a supervised weight loss program for at least six months before approving Wegovy. This step ensures that patients have attempted and failed non-pharmacological interventions, such as diet and exercise, before resorting to medication. Additionally, Aetna may limit coverage to a specific duration, such as 12-24 months, with the possibility of renewal if the patient demonstrates significant weight loss and improved health outcomes.

---

How Much Does Wegovy Cost With Aetna?

The cost of Wegovy with Aetna insurance can vary significantly depending on the patient’s specific plan, copay structure, and whether the medication is covered under the pharmacy or medical benefit. Without insurance, Wegovy can cost upwards of $1,300 per month, making it inaccessible for many patients. However, Aetna’s coverage can substantially reduce this cost, though out-of-pocket expenses may still apply.

For patients with Aetna insurance, the copay for Wegovy typically ranges from $25 to $100 per month, depending on the plan’s formulary tier. Wegovy is often placed on a higher tier, which may result in higher copays or coinsurance (e.g., 20-30% of the drug’s cost). Some Aetna plans may also require patients to meet a deductible before coverage kicks in, which can further impact the out-of-pocket cost.

In 2026, Aetna has introduced cost-sharing programs for Wegovy, such as copay cards or patient assistance programs, which can reduce the financial burden for eligible patients. For example, the Wegovy manufacturer, Novo Nordisk, offers a savings card that may lower the copay to as little as $0 for commercially insured patients. However, these programs often have income restrictions and may not be available to all Aetna members.

Patients should also be aware of potential prior authorization requirements, which can delay access to Wegovy and add administrative costs. It’s essential to review your Aetna plan details or contact customer service to understand your specific coverage and out-of-pocket responsibilities for Wegovy.

---

Wegovy Prior Authorization for Aetna

Prior authorization is a common requirement for Wegovy coverage under Aetna, designed to ensure that the medication is prescribed appropriately and cost-effectively. In 2026, Aetna’s prior authorization process for Wegovy typically involves several steps, including the submission of clinical documentation by the prescribing healthcare provider. This documentation must demonstrate that the patient meets Aetna’s coverage criteria, such as a BMI of 30 or higher (or 27 with comorbidities) and prior attempts at non-pharmacological weight loss interventions.

The prior authorization process for Wegovy often requires the following information:

1. Patient’s BMI and weight history: Documentation of the patient’s current BMI, weight trends, and any prior weight loss attempts.
2. Comorbid conditions: Evidence of weight-related comorbidities, such as type 2 diabetes, hypertension, or sleep apnea, which may justify the need for Wegovy.
3. Failed interventions: Proof that the patient has participated in a supervised weight loss program for at least six months without achieving clinically meaningful weight loss.
4. Prescriber’s rationale: A detailed explanation from the healthcare provider outlining why Wegovy is medically necessary for the patient, including potential benefits and risks.

Aetna’s prior authorization review for Wegovy typically takes 5-10 business days, though expedited reviews may be available in urgent cases. If the request is denied, Aetna must provide a written explanation, and the patient or provider has the right to appeal the decision. To streamline the process, healthcare providers can use Aetna’s online prior authorization portal or submit the required documentation via fax or mail.

---

How to Get Aetna to Cover Wegovy

Securing Aetna’s coverage for Wegovy requires a strategic approach, as the insurance provider’s policies are designed to ensure the medication is used appropriately and cost-effectively. Here are evidence-based steps to improve your chances of getting Aetna to cover Wegovy:

1. Confirm eligibility: Ensure you meet Aetna’s coverage criteria for Wegovy, such as a BMI of 30 or higher (or 27 with comorbidities) and prior attempts at non-pharmacological weight loss interventions. If you have type 2 diabetes, document your HbA1c levels and prior treatment failures to support an off-label request.

2. Work with your healthcare provider: Your doctor plays a critical role in securing Aetna’s approval for Wegovy. They must provide detailed documentation, including your medical history, weight trends, comorbid conditions, and prior weight loss attempts. A well-documented letter of medical necessity can significantly strengthen your case.

3. Submit prior authorization: Aetna requires prior authorization for Wegovy, so your healthcare provider must submit the necessary documentation through Aetna’s prior authorization portal or via fax/mail. Ensure all required information is included to avoid delays or denials.

4. Appeal if denied: If Aetna denies your request for Wegovy, you have the right to appeal the decision. Work with your healthcare provider to gather additional evidence, such as clinical trial data supporting Wegovy’s efficacy or letters from specialists, to strengthen your appeal.

5. Explore patient assistance programs: If Aetna’s coverage for Wegovy is limited or denied, consider applying for Novo Nordisk’s patient assistance program or copay savings card. These programs can reduce your out-of-pocket costs, though eligibility criteria apply.

6. Review your Aetna plan: Some Aetna plans may have more lenient coverage policies for Wegovy, so review your plan details or contact Aetna customer service to understand your specific benefits. If your plan does not cover Wegovy, you may consider switching to a different Aetna plan during open enrollment.

---

What to Do If Aetna Denies Wegovy

If Aetna denies your request for Wegovy, it’s essential to understand that this is not the end of the road. Insurance denials are common, but they can often be overturned through a well-prepared appeal. Here’s what to do if Aetna denies Wegovy coverage:

1. Review the denial letter: Aetna is required to provide a written explanation for the denial, including the specific reason(s) for the decision. Common reasons for denial include insufficient documentation, failure to meet coverage criteria, or lack of prior authorization. Carefully review the letter to identify the issue(s) that led to the denial.

2. Gather additional evidence: Work with your healthcare provider to gather additional documentation that addresses the reasons for denial. For example, if Aetna denied Wegovy due to insufficient evidence of prior weight loss attempts, your provider can submit records of supervised diet and exercise programs. If the denial was based on BMI criteria, your provider can provide updated measurements or documentation of weight-related comorbidities.

3. Submit an appeal: Aetna’s appeal process typically involves submitting a written request, along with supporting documentation, to challenge the denial. Your healthcare provider can help draft a compelling appeal letter that highlights the medical necessity of Wegovy and references clinical guidelines or trial data supporting its use. Appeals must be submitted within a specific timeframe, so act quickly to avoid missing the deadline.

4. Request an external review: If Aetna upholds the denial after your initial appeal, you have the right to request an external review by an independent third party. This process involves submitting your case to an outside organization, which will evaluate the denial and make a final determination. External reviews are binding, meaning Aetna must comply with the decision.

5. Explore alternative options: While pursuing an appeal, consider alternative treatments or financial assistance programs. For example, Novo Nordisk offers a Wegovy savings card that can reduce out-of-pocket costs for eligible patients. Additionally, your healthcare provider may recommend alternative medications, such as Saxenda (liraglutide) or Qsymia (phentermine-topiramate), which may have different coverage policies under Aetna.

---

Aetna Alternatives If Wegovy Is Not Covered

If Aetna denies coverage for Wegovy and appeals are unsuccessful, patients still have several alternatives to explore. These options include other weight loss medications, lifestyle interventions, or switching to a different insurance provider with more favorable coverage policies for Wegovy.

1. Alternative weight loss medications: Several FDA-approved medications for weight loss may be covered by Aetna, even if Wegovy is not. These include:

   • Saxenda (liraglutide): A GLP-1 receptor agonist similar to Wegovy, approved for chronic weight management. Saxenda is often covered by Aetna, though prior authorization may still be required.
   • Qsymia (phentermine-topiramate): A combination medication that suppresses appetite and promotes weight loss. Qsymia is typically covered by Aetna but may have restrictions based on BMI and comorbid conditions.
   • Contrave (naltrexone-bupropion): A combination medication that targets the brain’s reward system to reduce food cravings. Contrave may be covered by Aetna, though prior authorization is often required.

2. Lifestyle interventions: If medication is not an option, Aetna may cover lifestyle interventions, such as medically supervised weight loss programs, nutrition counseling, or bariatric surgery. These programs can be effective for some patients, though they may not provide the same level of weight loss as Wegovy.

3. Switching insurance providers: If Aetna’s coverage for Wegovy is consistently denied, patients may consider switching to a different insurance provider during open enrollment. Some insurers, such as UnitedHealthcare or Blue Cross Blue Shield, may have more lenient coverage policies for Wegovy. However, it’s essential to review the new plan’s formulary and prior authorization requirements before making the switch.

4. Patient assistance programs: Novo Nordisk offers a Wegovy savings card that can reduce out-of-pocket costs for eligible patients. Additionally, the company’s patient assistance program may provide Wegovy at no cost for uninsured or underinsured patients who meet income criteria.

5. Clinical trials: Patients who are unable to access Wegovy through insurance or financial assistance may consider enrolling in a clinical trial. Novo Nordisk and other pharmaceutical companies often conduct trials for new weight